![Natalie McNamee](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Natalie McNamee
Private Equity Investor bei Tarnagulla Ventures Pty Ltd.
Profil
Natalie has been a Director of Tarnagulla Ventures Pty Ltd since 2015.
She had led the investment diligence into most of the portfolio companies since then, including Lubris BioPharma, a company which has since successfully licensed their lead indication to Novartis.
Prior to returning to Australia, Natalie worked for Tocagen Inc, a gene therapy company, based in San Diego, in their business development team whilst finishing her Masters.
She then worked as a bioengineer at the then-newly formed Quanticel Pharmaceuticals, a cancer stem cell focused drug developer.
Quanticel was acquired by Celgene for $485M in 2015.
Natalie received her Masters in Bioengineering at UC San Diego and a dual Bachelor of Finance and Mechanical Engineering from Melbourne University.
Aktive Positionen von Natalie McNamee
Unternehmen | Position | Beginn |
---|---|---|
Tarnagulla Ventures Pty Ltd.
![]() Tarnagulla Ventures Pty Ltd. Investment ManagersFinance Tarnagulla Ventures Pty Ltd (Tarnagulla Ventures) is a venture capital firm founded in 2015. The firm is headquartered in Melbourne, Australia. | Private Equity Investor | 01.01.2015 |
Ehemalige bekannte Positionen von Natalie McNamee
Unternehmen | Position | Ende |
---|---|---|
JUPITER NEUROSCIENCES, INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Natalie McNamee
University of California San Diego | Graduate Degree |
University of Melbourne | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Jupiter Neurosciences, Inc.
![]() Jupiter Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company. Its therapeutic candidate, JOTROL is applicable to many central nervous system diseases, including Alzheimer’s disease and traumatic brain injury. The company was founded by Christer Rosén, Alexander Rosén, Claes Wahlestedt, Marshall Hayward, and Shaun P. Brothers in June 2015 and is headquartered in Jupiter, FL. | Health Technology |
Tarnagulla Ventures Pty Ltd.
![]() Tarnagulla Ventures Pty Ltd. Investment ManagersFinance Tarnagulla Ventures Pty Ltd (Tarnagulla Ventures) is a venture capital firm founded in 2015. The firm is headquartered in Melbourne, Australia. | Finance |